It has been shown that TGF-β neutralizing antibodies, antisense TGF-β oligodeoxynucleotides, soluble human TβRII (sTβRII.Fc) and specific inhibitors to TβR kinases (such as GW788388 and IN-1130) can effectively halt the progression of renal fibrosis in a number of experimental kidney disease models. This evidence concerns the gene TGFB1 and kidney disorder.